Peter Bramlage

Summary

Publications

  1. pmc Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline
    Peter Bramlage
    Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany
    Cardiovasc Diabetol 9:53. 2010
  2. pmc Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients--an analysis of the DiaRegis registry
    Diethelm Tschöpe
    Herz und Diabeteszentrum Nordrhein Westfalen in Bad Oeynhausen, Universitätsklinik der Ruhr Universität, Bochum, Germany
    Cardiovasc Diabetol 10:66. 2011
  3. pmc Age- and sex-specific prevalence and ten-year risk for cardiovascular disease of all 16 risk factor combinations of the metabolic syndrome - A cross-sectional study
    Susanne Moebus
    Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, University Duisburg Essen, Germany
    Cardiovasc Diabetol 9:34. 2010
  4. pmc Bone morphogenetic protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis
    Carsten P Bramlage
    Department of Medicine, Nephrology and Rheumatology, Georg August University Gottingen, Robert Koch Strasse 40, 37075 Gottingen, Germany
    BMC Nephrol 11:31. 2010
  5. pmc Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY
    Sylvia Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Germany
    BMC Cancer 11:316. 2011
  6. doi request reprint Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care
    Peter Bramlage
    Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany
    Expert Opin Pharmacother 11:2779-90. 2010
  7. doi request reprint A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients
    Peter Bramlage
    Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany
    J Clin Hypertens (Greenwich) 12:666-77. 2010
  8. pmc Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice
    Peter Bramlage
    Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany
    Vasc Health Risk Manag 6:803-11. 2010
  9. doi request reprint Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan
    Peter Bramlage
    Institute for Cardiovascular Pharmacology and Epidemiology, Menzelstrasse 21, 15831 Mahlow, Germany
    Expert Opin Pharmacother 11:521-35. 2010
  10. doi request reprint Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension
    Peter Bramlage
    Institute for Cardiovascular Pharmacology and Epidemiology, Menzelstrasse 21, 15831 Mahlow, Germany
    Expert Opin Pharmacother 10:1755-67. 2009

Collaborators

Detail Information

Publications22

  1. pmc Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline
    Peter Bramlage
    Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany
    Cardiovasc Diabetol 9:53. 2010
    ..Data from clinical practice with respect to this patient group are however scarce. Therefore we set up a registry in primary care documenting the course and outcomes of this patient group...
  2. pmc Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients--an analysis of the DiaRegis registry
    Diethelm Tschöpe
    Herz und Diabeteszentrum Nordrhein Westfalen in Bad Oeynhausen, Universitätsklinik der Ruhr Universität, Bochum, Germany
    Cardiovasc Diabetol 10:66. 2011
    ..We aimed to identify predictors of anamnestic hypoglycaemia in type-2 diabetic patients on oral mono- or dual oral combination antidiabetic pharmacotherapy...
  3. pmc Age- and sex-specific prevalence and ten-year risk for cardiovascular disease of all 16 risk factor combinations of the metabolic syndrome - A cross-sectional study
    Susanne Moebus
    Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, University Duisburg Essen, Germany
    Cardiovasc Diabetol 9:34. 2010
    ....
  4. pmc Bone morphogenetic protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis
    Carsten P Bramlage
    Department of Medicine, Nephrology and Rheumatology, Georg August University Gottingen, Robert Koch Strasse 40, 37075 Gottingen, Germany
    BMC Nephrol 11:31. 2010
    ..Bone Morphogenetic Protein (BMP)-7 is protective in different animal models of acute and chronic kidney disease. Its role in human kidneys, and in particular hypertensive nephrosclerosis, has thus far not been described...
  5. pmc Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY
    Sylvia Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Germany
    BMC Cancer 11:316. 2011
    ..Patients with cancer have an increased risk of VTE. We compared VTE rates and bleeding complications in 1) cancer patients receiving LMWH or UFH and 2) patients with or without cancer...
  6. doi request reprint Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care
    Peter Bramlage
    Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany
    Expert Opin Pharmacother 11:2779-90. 2010
    ..Research design and methods. Multicenter, noninterventional, noncontrolled observational study in 8241 patients seen by 2187 physicians over 12 - 18 weeks...
  7. doi request reprint A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients
    Peter Bramlage
    Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany
    J Clin Hypertens (Greenwich) 12:666-77. 2010
    ..The present data illustrate the potential for an improvement of blood pressure treatment and control in daily cardiology practice...
  8. pmc Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice
    Peter Bramlage
    Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany
    Vasc Health Risk Manag 6:803-11. 2010
    ..To assess the efficacy and tolerability of a fixed-dose combination of olmesartan and amlodipine in an unselected population of patients in primary care and to compare the results with recent randomized controlled trial evidence...
  9. doi request reprint Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan
    Peter Bramlage
    Institute for Cardiovascular Pharmacology and Epidemiology, Menzelstrasse 21, 15831 Mahlow, Germany
    Expert Opin Pharmacother 11:521-35. 2010
    ..We aimed at an in-depth comparison of two frequently used angiotensin receptor blockers to provide evidence for this decision...
  10. doi request reprint Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension
    Peter Bramlage
    Institute for Cardiovascular Pharmacology and Epidemiology, Menzelstrasse 21, 15831 Mahlow, Germany
    Expert Opin Pharmacother 10:1755-67. 2009
    ..Side effects offset these data, and compelling indications may have favored the outcomes. Comparisons in a more unselected patient population are needed to define the role of particular drug-drug combinations...
  11. pmc Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension
    Peter Bramlage
    Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany
    Vasc Health Risk Manag 5:213-24. 2009
    ..FD irbesartan/HCTZ is thus a valuable addition to the clinician's armamentarium for the management of hypertension and should help more patients achieve their BP target...
  12. pmc Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice
    Peter Bramlage
    Institut für Pharmakologie und präventive Medizin, Mahlow, Germany
    Vasc Health Risk Manag 9:475-83. 2013
    ..The aims of the present study were to confirm these data in an unselected patient population in daily practice and to determine the impact of physical activity on blood pressure control...
  13. pmc Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia
    Peter Bramlage
    Institut für Pharmakologie und präventive Medizin, Menzelstrasse 21, 15831 Mahlow, Germany
    Cardiovasc Diabetol 11:122. 2012
    ..We aimed at identifying variables predicting hypoglycemia in elderly type 2 diabetic patients and the relation to HbA1c values achieved...
  14. doi request reprint Prognosis of patients with atrial fibrillation undergoing percutaneous coronary intervention receiving drug eluting stents
    Peter Bramlage
    Institut für Pharmakologie und präventive Medizin, Mahlow, Germany
    Clin Res Cardiol 102:289-97. 2013
    ..Aim of the present analysis was to investigate the prognostic impact of AF in patients undergoing drug eluting stent (DES) implantation during a 1-year follow-up...
  15. pmc Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy--an analysis of the DiaRegis registry
    Jürgen Wasem
    Lehrstuhl für Medizinmanagement, Universitat Duisburg Essen, Essen, Germany
    Cardiovasc Diabetol 12:47. 2013
    ..Type-2 diabetes mellitus has a major impact on health related quality of life (HRQoL). We aimed to identify patient and treatment related variables having a major impact...
  16. doi request reprint The value of irbesartan in the management of hypertension
    Peter Bramlage
    Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany
    Expert Opin Pharmacother 10:1817-31. 2009
    ..In addition observational data from clinical practice and proven end-organ protection in diabetic nephropathy provides further evidence of the true value of irbesartan compared to other ARBs in the treatment of hypertension...
  17. ncbi request reprint Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide
    Peter Bramlage
    Institut für Pharmakologie und präventive Medizin, Menzelstrasse 21, 15831, Mahlow, Germany
    Clin Drug Investig 34:403-11. 2014
    ..The aim of the present study was to verify those data in a large real-world sample of hypertensive patients and to cross-check adherence evaluation performed by physicians and patients self-assessment...
  18. ncbi request reprint [Atrial fibrillation in Germany--epidemiology, diagnosis, treatment and costs]
    Karin Bramlage
    Institut für Pharmakologie und präventive Medizin, Menzelstrasse 21, 15831 Mahlow, Duisburg Essen
    Med Monatsschr Pharm 36:215-24; quiz 225-6. 2013
    ..The aim of this review is to give a practical overview of the epidemiology, diagnosis, treatment and costs to pharmacists who have a key role in the implementation of pharmacotherapy of atrial fibrillation...
  19. doi request reprint Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2)
    Peter Bramlage
    Institut für Pharmakologie und präventive Medizin, Mahlow, Cloppenburg, Germany
    J Clin Hypertens (Greenwich) 16:41-6. 2014
    ..Patients of Caucasian ethnicity with moderate essential hypertension uncontrolled on candesartan experienced a further drop in BP using olmesartan and amlodipine...
  20. pmc Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review
    Peter Bramlage
    Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany
    Cardiovasc Diabetol 8:18. 2009
    ..This review explores the blood pressure reduction and persistence with treatment of antihypertensive drugs and the cost consequences of poor persistence with pharmaceutical interventions in arterial hypertension...
  21. doi request reprint Candesartan cilexetil 32 mg/hydrochlorothiazide 25 mg in unselected patients with high or very high cardiovascular risk: efficacy, safety, and metabolic impact
    Peter Bramlage
    Institut für Pharmakologie und präventive Medizin, Menzelstrasse 21, 15831, Mahlow, Germany
    Clin Drug Investig 34:241-9. 2014
    ..The primary objective was the efficacy of candesartan cilexetil 32 mg/hydrochlorothiazide 25 mg in lowering the office-based blood pressure (BP). Secondary objectives were changes of metabolic parameters and safety...
  22. pmc Improved survival of patients with coronary artery disease and low ejection fraction with ICD implantation versus conventional therapy in a real world survey
    Timo Aschenbrenner
    Institut für Pharmakologie und präventive Medizin, Mahlow, Germany
    BMC Res Notes 5:382. 2012
    ..We aimed to validate that these results also apply to patients of a typical community hospital in Germany...